Roberto Iacovelli, Medical Oncologist at Gemelli Polyclinic Foundation IRCCS, and Associate Professor of Medical Oncology at Catholic University, Comprehensive Cancer Center of Rome, Italy, shared on X:
“It was a great honor to be invited at EMUC26 for discussing therapy after adjuvant IO for RCC amog a great panel of colleagues.
See you nex year!”
At EMUC26, Roberto Iacovelli highlighting that approximately 40% of patients experience recurrence within five years after surgery for localized renal cell carcinoma (RCC), while around 15% progress during adjuvant immunotherapy (IO).
He emphasized that patients with refractory disease or early progression should not routinely be re-exposed to IO-based combinations. The same approach may be considered for patients with intermediate progression (up to six months). In these settings, cabozantinib or lenvatinib plus belzutifan are his preferred treatment options.
For patients progressing beyond these time points, he noted that there is no established standard of care. VEGFR-TKI therapy is recommended, although VEGFR-TKI plus IO combinations may also be reasonable. He highlighted the need for prospective evidence, with future studies focusing on novel combinations and better defining the role of IO rechallenge.
You can also read: Adjuvant Therapy in Renal Cell Carcinoma: Who Benefits and Who Is Overtreated
